FPT to Become E.ON’s Strategic Partner for SAP Identity Management Managed Service
FPT Europe, a subsidiary of the global technology services provider FPT Corporation, has become a strategic partner for E.ON Group in the area of digital transformation and SAP IDM Managed Services. According to the five-year contract, FPT will support E.ON on both legacy and new SAP environments at the corporate-wide level. The project will be delivered with FPT's best-shore model as SAP experts from FPT Germany (onsite), FPT Slovakia (nearshore) and the offshore delivery team in Vietnam will work together to assure the timely manner in responding to customer’s requests, provide excellent services with no communication barrier and time zone difference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005041/en/
F-Town 3 Campus of FPT Software (Photo: Business Wire)
Tailor-made services
Within the contract framework, FPT provides administration and maintenance of SAP functions in the Governance, Risk Management and Compliance (GRC) Operations. In addition, the IT experts manage user access authorizations through systematic User Authorization Management, develop and manage user roles as part of service Role Administration & Development. Moreover, FPT provides Security, Data Protection, Audit & Compliance Support as well as handles all related on-call Duty services.
By working with FPT, E.ON benefits from an optimized service delivery model and experienced technology experts who speak local language. The newly-signed contract also proves FPT’s outstanding service-level agreement which complies with the European General Data Protection Regulation.
FPT as a trusted partner in SAP for large enterprises
"In the course of the supplier consolidation and process optimization around SAP Identity @ Access Management, FPT was selected as our future supplier within the scope of a tender. The offer itself and the transition approach corresponded to what we as E.ON expect.
The operational topics of incident management and role building were awarded for a variety of SAP environments. Additional agreed services are in areas of audit and ICS/SOD support as well as application support for SAP IDM @ GRC Technology.
Past experience has shown that FPT has knowledge in most areas and is therefore also able to serve the E.ON world. The new topics were tackled quickly by FPT, and the transition phase is well progressed.
The aim is to have FPT on board as a reliable and SLA-loyal partner in this area from 01.11.2021. For the start of this managed service, we wish a lot of success, a motivated team and a good cooperation." summarized Dieter Bürgel, Head of Corporate Digital Services at E.ON the support engagement with FPT.
"This contract with E.ON demonstrates our ability to provide application managed services to large enterprises in Germany and Europe," said Le Hai, CEO of FPT Europe. "The key factor for success lies in the expertise and experience of our experts in SAP IDM Managed Services. We also effectively apply the best-shore model by combining our talent pools in Germany and Slovakia with the delivery team in Vietnam to achieve competitive advantages."
"We made great effort to find solutions to the difficulties encountered in preparing for this important contract," affirmed Andy Do, Deputy Director/ Head of Delivery at FPT Europe. "In particular, we invested early in recruiting experts for our Center of Excellence and trained our current employees to improve their SAP IDM Managed Services skills. And with all of this good preparation, we prove that FPT is able to meet the customer's high requirements and successfully win their trust."
About FPT Deutschland GmbH
Headquartered in Essen, Germany, FPT Deutschland GmbH is part of FPT Corporation, a technology and IT services provider headquartered in Vietnam with 36,000 employees and revenues of approximately $2 billion. As the pioneer in digital transformation, the company offers world-class services in smart factory, digital platforms, RPA (robotic process automation), artificial intelligence (AI), IoT (Internet of Thing), Data Analytics, Mobility, Cloud, Managed Services And Testing. FPT Software serves more than 700 customers worldwide, including 100 of which are Fortune 500 companies in the Aerospace, Automotive, Banking And Finance, Communications, Media And Services, Logistics And Transportation, Utilities, Consumer Products, Healthcare, Manufacturing, Public Sector, Technology, etc. Founded in 2012, FPT Europe is a technology partner of 50 leading companies, including RWE, Allianz, Siemens, Schaeffler, Airbus and Carlsberg,etc. For more information, visit: www.fpt-europe.de.
About E.ON
E.ON is a privately owned international energy company headquartered in Essen, Germany, that focuses on the business areas of energy networks and customer solutions. As one of the largest energy companies in Europe, E.ON plays a leading role in shaping a green, digital and decentralized energy world. Around 75,000 employees develop and sell products and solutions for residential, commercial and industrial customers. More than 50 million customers purchase electricity, gas, digital products or solutions for electromobility, energy efficiency and climate protection from E.ON. As an innovation leader, E.ON offers its customers the latest technology solutions and promotes cross-industry partnerships in the energy sector and beyond. More information at www.eon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005041/en/
Contact information
FPT Deutschland GmbH
Linh Pham
Head of Marketing & Communications
LinhPTK@fsoft.com.vn
FPT Software Presseservice
Lewis Communications GmbH
+49 211 882 476 00
FPT_DE@teamlewis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release
Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom